focus -WSS

focus

author：comprehensive 2025-09-27 22:18:13 - browse：584

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Latest bird flu infection made farmworker sicker than earlier cases

focus

WSS

David Sabatini, ex

iTeos Therapeutics debuts first data on TIGIT

Insmed lung disease drug hits target in key Phase 3 trial

AI used to predict Covid

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Antibiotic resistance nearly killed me, so I'm raising awareness of it

hotspot

focus

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Digital health: a case of mistaken identity

Alkermes shareholders re

As a primary care physician, here's how I hope to partner with AI

Apple is now the first public company to be valued at $3 trillion

Prosthetic arm enables patients to feel the objects they grip

Medical records are filled with copy

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Anesthesiologist group: stop taking Ozempic before surgery

Biohaven protein

hotspot

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Adam's Biotech Scorecard: Do Sarepta's exon

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Average age of first period drops to 11.9 years, study shows

David Sabatini, ex

hotspot

focus

focus

hotspot